Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample

BackgroundTreatment of heart failure (HF) is particularly complex in the presence of comorbidities. We sought to identify and associate comorbidity profiles with inpatient outcomes during HF hospitalizations.MethodsLatent mixture modeling was used to identify common profiles of comorbidities during adult hospitalizations for HF from the 2009 Nationwide Inpatient Sample (n = 192,327).ResultsMost discharges were characterized by "common" comorbidities. A "lifestyle" profile was characterized by a high prevalence of uncomplicated diabetes, hypertension, chronic pulmonary disorders and obesity. A "renal" profile had the highest prevalence of renal disease, complicated diabetes, and fluid and electrolyte imbalances. A "neurovascular" profile represented the highest prevalence of cerebrovascular disease, paralysis, myocardial infarction and peripheral vascular disease. Relative to the common profile, the lifestyle profile was associated with a 15% longer length of stay (LOS) and 12% greater cost, the renal profile was associated with a 30% higher risk of death, 27% longer LOS and 24% greater cost, and the neurovascular profile was associated with a 45% higher risk of death, 34% longer LOS and 37% greater cost (all p < 0.001).ConclusionsComorbidity profiles are helpful in identifying adults at higher risk of death, longer length of stay, and accumulating greater costs during hospitalizations for HF.

[1]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[2]  R. Ziegelstein Depression after myocardial infarction. , 1995, Cardiology in review.

[3]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[4]  T. Wadden,et al.  Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. , 2014, Journal of the American Pharmacists Association : JAPhA.

[5]  D. Kitzman,et al.  Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management , 2012, Heart Failure Reviews.

[6]  Harlan M Krumholz,et al.  Trends in comorbidity, disability, and polypharmacy in heart failure. , 2011, The American journal of medicine.

[7]  Beatrice A. Golomb,et al.  Peripheral Arterial Disease: Morbidity and Mortality Implications , 2006, Circulation.

[8]  N. Duan Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[9]  P. Abete,et al.  Charlson Comorbidity Index does not predict long-term mortality in elderly subjects with chronic heart failure. , 2009, Age and ageing.

[10]  C. Ritchie,et al.  Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. , 2009, The American journal of cardiology.

[11]  N. Bayley,et al.  Failure , 1890, The Hospital.

[12]  C. Ronco,et al.  The Cardiorenal Syndrome , 2011, International journal of nephrology.

[13]  E. Grossi BMC Cardiovascular Disorders , 2007 .

[14]  Peter C Austin,et al.  Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research , 2005, Medical care.

[15]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[16]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[17]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[18]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[19]  Tony Jung,et al.  An introduction to latent class growth analysis and growth mixture modeling. , 2008 .

[20]  Ulf Dahlström,et al.  Frequent non‐cardiac comorbidities in patients with chronic heart failure , 2005, European journal of heart failure.

[21]  W. Tang,et al.  Management of comorbid conditions in heart failure: a review. , 2012, The Medical clinics of North America.

[22]  F. Triposkiadis,et al.  Prevalence and Importance of Comorbidities in Patients With Heart Failure , 2012, Current Heart Failure Reports.

[23]  D. Mannino,et al.  The epidemiology and economics of chronic obstructive pulmonary disease. , 2007, Proceedings of the American Thoracic Society.

[24]  Li Liang,et al.  A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program , 2010, Circulation. Cardiovascular quality and outcomes.

[25]  D. Hedeker A mixed‐effects multinomial logistic regression model , 2003, Statistics in medicine.

[26]  William Encinosa,et al.  [Table, Diagnoses, ICD-9-CM, and Clinical Classifications Software (CCS), and Diagnosis-Related Groups (DRGs)]. , 2008 .

[27]  E. Ferrannini,et al.  Pathophysiology, Prevention and Management of Chronic Kidney Disease in the Hypertensive Patient With Diabetes Mellitus , 2011, Journal of clinical hypertension.

[28]  C. Lang,et al.  Non-cardiac comorbidities in chronic heart failure , 2006, Heart.

[29]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.

[30]  D. Rubin,et al.  Testing the number of components in a normal mixture , 2001 .

[31]  Elizabeth S. Chen,et al.  Determining Compound Comorbidities for Heart Failure from Hospital Discharge Data , 2012, AMIA.

[32]  B. Starfield,et al.  Defining Comorbidity: Implications for Understanding Health and Health Services , 2009, The Annals of Family Medicine.

[33]  S. Solomon,et al.  Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. , 2013, International journal of cardiology.

[34]  Jessica Ogarek,et al.  Patterns of Comorbidity in Older Adults with Heart Failure: The Cardiovascular Research Network PRESERVE Study , 2013, Journal of the American Geriatrics Society.

[35]  Albert W Wu,et al.  Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[36]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[37]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[38]  Nilam Ram,et al.  Methods and Measures: Growth mixture modeling: A method for identifying differences in longitudinal change among unobserved groups , 2009, International journal of behavioral development.

[39]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[40]  Mark A. Hlatky,et al.  ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure , 2005 .

[41]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[42]  R. Schrier,et al.  Cardiorenal syndrome in acute decompensated heart failure. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[43]  Michael Böhm,et al.  Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. , 2013, International journal of cardiology.

[44]  B. Muthén,et al.  Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study , 2007 .

[45]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[46]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[47]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[48]  Manfred Stommel,et al.  "Concordance between comorbidity data from patient self-report interviews and medical record documentation" , 2008, BMC health services research.

[49]  Sangeeta C. Ahluwalia,et al.  Impact of Comorbidity on Mortality Among Older Persons with Advanced Heart Failure , 2012, Journal of General Internal Medicine.

[50]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[51]  K. Krishnan,et al.  Cerebrovascular disease and depression symptoms in the cardiovascular health study. , 1999, Stroke.